Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
Vincent Lo Re, III, MD

Vincent Lo Re, III, MD Physician

Assistant Professor of Medicine
Assistant Professor of Epidemiology in Biostatistics and Epidemiology

Languages spoken:

  • French

Dr. Lo Re is a Penn Medicine employed physician.

About Dr. Vincent Lo Re, III

Recognized by Best Doctors in America 2007-2008, 2009-2010, 2011-2012

Clinical Specialties

Specialty:

  • Medicine
    • Infectious Diseases

Programs & Centers:

Board Certification:

  • Infectious Disease, 2003

Clinical Expertise:

  • Hepatitis C
  • HIV and AIDS

Description of Clinical Expertise

Viral hepatitis; HIV/hepatitis C coinfection; HIV/hepatitis B coinfection; drug-induced liver injury

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Fellowship: Hospital of the University of Pennsylvania
Medical School: University of Pennsylvania School of Medicine
Residency: Hospital of the University of Pennsylvania

Memberships

AIDS Clinical Trials Group (ACTG) Hepatitis External Advisory Committee, National American Association for the Study of Liver Diseases, National American College of Epidemiology, National American College of Physicians, National American Conference for the Treatment of HIV, National Department of Health & Human Services, US Food and Drug Administration (FDA), National HIV Medical Association, National Infectious Diseases Society of America (IDSA), National Institute of Medicine (IOM) Committee for a National Strategy for the Elimination of Hepatitis B and C, National International AIDS Society, International International Conference for Pharmacoepidemiology Scientific Program Committee, International International Society for Pharmacoepidemiology, International North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), National Society for Epidemiologic Research, National Veterans Aging Cohort Study (VACS), National

Hospital Affiliation

Dr. Lo Re is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

Research Interests
- Hepatic and non-hepatic outcomes of chronic hepatitis B and C, particularly among patients with HIV infection
- Adherence to hepatitis C virus therapy
- Hepatotoxicity of medications
- Evaluation of clinical outcomes
- Population-based and administrative databases

Key Words
HIV/viral hepatitis coinfection; hepatitis B; hepatitis C; HIV/AIDS; epidemiology; clinical outcomes; pharmacoepidemiology

Description of Research
Dr. Lo Re’s research focuses on clinical outcomes of chronic viral hepatitis infection in HIV-infected patients. He is conducting epidemiologic studies to examine novel risk factors for decompensated cirrhosis among HIV/hepatitis C-coinfected patients and is working to develop and internally validate a clinical predictive index to stratify HIV/hepatitis C patients according to their risk of progression to hepatic decompensation. He has also examined the prevalence, risk factors, and clinical significance of occult hepatitis B virus infection in HIV-infected patients. Additional studies are examining non-hepatic outcomes of chronic viral hepatitis infection in HIV, particularly abnormalities in bone mineral density and fractures.

Dr. Lo Re also evaluates clinical outcomes of hepatitis therapy in the setting of HIV. Recent work has examined the incidence and risks factors for anemia and weight loss during hepatitis C therapy among HIV-infected patients. Another active area of research is adherence to combination pegylated interferon and ribavirin hepatitis C therapy, specifically examining the levels of adherence required for maximal hepatitis C suppression and risk factors for poor adherence to these therapies.

Methodologic interests include use of population-based databases for epidemiologic research, ascertainment and adjudication of clinical outcomes, and pharmacoepidemiology.

Selected Publications:

Lo Re V 3rd, Gowda C, Urick PN, Halladay JT, Binkley A, Carbonari DM, Battista K, Peleckis C, Gilmore J, Roy JA, Doshi JA, Reese PP, Reddy KR, Kostman JR: Disparities in absolute denial of modern hepatitis C therapy by type of insurance Clin Gastroenterol Hepatol 14 : 1035-4,2016.

Lo Re V 3rd, Carbonari DM, Lewis JD, Forde KA, Goldberg DS, Reddy KR, Haynes K, Roy JA, Sha D, Marks AR, Schneider JL, Strom BL, Corley DA: Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status Am J Med 129 : 283-91,2016.

Lo Re V 3rd, Haynes K, Forde KA, Goldberg DS, Lewis JD, Carbonari DM, Leidl KBF, Reddy KR, Nezamzadeh MS, Roy J, Sha D, Marks AR, De Boer J, Schneider JL, Strom BL, Corley DA: Risk of acute liver failure in in patients with drug-induced liver injury: Evaluation of Hy's Law and a new prognostic model Clin Gastroenterol Hepatol 13 : 2360–8,2015.

Goldberg DS, Forde KA, Haynes K, Lewis JD, Carbonari DM, Leidl KBF, Nezamzadeh MS, Reddy KR, Roy J, Sha D, Marks AR, De Boer J, Strom BL, Corley DA, Lo Re V 3rd: Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated healthcare system Gastroenterology 148 : 1353-61,2015.

Lo Re V 3rd, Kallan MJ, Tate J, AR Localio, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC: Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study Ann Intern Med 160 : 369-79,2014.

Lim JK, Tate J, Fultz SL, Goulet JL, Rimland D, Conigliaro J, Bryant KJ, Gordon AJ, Gibert C, Fiellin DA, Justice AC, Lo Re V 3rd: Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus–infected, and uninfected patients Clin Infect Dis 58 : 1449-58,2014.

Hafkin JS, Osborn MK, Localio AR, Amorosa VK, Kostman JR, Stern JJ, De La Torre P, Mounzer K, Frank I, Gross R, Chang KM, Lo Re V 3rd: Incidence and risk factors for incomplete hepatitis B virus DNA suppression in HIV/hepatitis B-coinfected patients receiving tenofovir-based antiretroviral therapy J Viral Hepat 21 : 288-96,2014.

Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KBF, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re V 3rd: Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection J Hepatol 61 : 210-8,2014.

Lo Re V 3rd, Volk J, Newcomb CW, Yang YX, Freeman CP, Hennessy S, Kostman JR, Tebas P, Leonard MB, Localio AR: Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/HIV coinfection Hepatology 56 : 1688-98,2012.

Lo Re V 3rd, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R: Relationship between adherence to hepatitis C virus therapy and virologic outcomes Ann Intern Med 155 (6): 353-60,2011.

View all publications

Academic Contact Info

Center for Clinical Epidemiology and Biostatistics
836 Blockley Hall
423 Guardian Drive

Philadelphia, PA 19104
Fax: (215) 349-5111
Patient appointments: 800-789-PENN (7366)

Related Links